Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

Core Insights - Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [1][3] - The company will hold a conference call and webcast to discuss the results of the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) on September 8, 2025 [1] Company Overview - Dianthus Therapeutics is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [3] - The company aims to design and deliver novel, best-in-class monoclonal antibodies with improved selectivity and potency for treating severe autoimmune and inflammatory diseases [3]